University of Louisville Research Foundation, Inc.

Other

Genentech, Inc.

Jon B Klein

Michael L Merchant

Elias Klein

Michael E Brier

Adam E Gaweda

Rosemary Ouseph

Richard A Ward

Grzegorz Boratyn

A David Slater

Christine W Czarniecki

George Harding

Gerald Sonnenfeld

Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent.

Methods and kits for predicting a response to an erythropoietic agent

The presently-disclosed subject matter provides methods for diagnosing a cardiovascular disease in a subject by determining an amount of one or more peptide biomarkers disclosed herein in a biological sample from the subject. The presently-disclosed subject matter further provides methods for determining treatment efficacy and/or progression of a cardiovascular disease in a subject by measuring amounts of one or more of the biomarkers in a biological sample from the subject. The presently-disclosed subject matter also provides antibodies and kits for measuring the biomarkers.

Peptide biomarkers of cardiovascular disease

Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17.

Methods of isolating membrane vesicles from a biological fluid sample are provided. In some embodiments, the methods comprise providing a biological fluid sample comprising membrane vesicles; filtering the biological fluid sample through a filtration module comprising a filter having an average pore diameter of between about 0.01 um and about 0.15 um; and collecting from the filtration module a retentate comprising the membrane vesicles, thereby isolating the membrane vesicles from the biological fluid sample.

Isolation of membrane vesicles from biological fluids and methods of using same

Methods and kits are provided for diagnosing a kidney disease, or the risk thereof, in a subject. The methods include determining an amount of at least one peptide biomarker disclosed herein in a biological sample from the subject and comparing the amount of the at least one peptide in the sample with a control level, wherein if the amount determined is different than the control level, the subject is diagnosed as having, or at an increased risk of developing, the kidney disease.

Peptide biomarkers predictive of renal function decline and kidney disease

Methods for diagnosing a kidney disease, or the risk thereof, in a subject are provided. The methods comprise determining an amount of at least one peptide biomarker disclosed herein in a biological sample from the subject and comparing the amount of the at least one peptide in the sample with a control level, wherein if the amount determined is different than the control level, the subject is diagnosed as having, or at an increased risk of developing, the kidney disease.

The present invention relates generally to the electrophoretic separation of biomolecules, including but not limited to proteins, peptides, DNA and RNA. The methods of this invention are particularly useful when applied to two-dimensional gel electrophoresis.

Electrophoresis gel support

A method and apparatus for supplying power to a computer, and initiating loading of software in the computer in response to a first signal. The invention allows a fax to be received, or a modem session initiated by a computer while the computer is unattended and powered down. The invention initiates the loading of the appropriate software in the computer for conducting the incoming session. The invention also directs incoming calls so that only one phone line is required for voice, fax, and modem sessions.

Method and apparatus for initiating loading of software in a personal

The invention relates in general to the prevention and treatment of microbial infections in transplant patients. More particularly, the invention concerns the use of lymphokines, and specifically gamma interferon (IFN-.gamma.) for the prophylaxis and treatment of microbial infections in transplant recipients, without increasing the incidence of graft rejections.

Growing community of inventors

Louisville, KY, United States of America

Jon B Klein